Parathyroid hormone alleviates non-alcoholic liver steatosis via activating the hepatic cAMP/PKA/CREB pathway

Parathyroid hormone alleviates non-alcoholic liver steatosis via activating the hepatic cAMP/PKA/CREB pathway

Non-alcoholic fatty liver disease (NAFLD), hallmarked by liver steatosis, is becoming a global concern, but effective and safe drugs for NAFLD are still lacking at present. Parathyroid hormone (PTH), the only FDA-approved anabolic treatment for osteoporosis, is important in calcium-phosphate homeost...

Volledige beschrijving

Bibliografische gegevens
Hoofdauteurs: Xu Feng, Ye Xiao, Qi Guo, Hui Peng, Hai-Yan Zhou, Jian-Ping Wang, Zhu-Ying Xia
Formaat: Artikel
Taal:English
Gepubliceerd in: Frontiers Media S.A. 2022-08-01
Reeks:Frontiers in Endocrinology
Onderwerpen:
parathyroid hormone
non-alcoholic liver steatosis
therapeutics
PTH1R
PKA/CREB pathway
Online toegang:https://www.frontiersin.org/articles/10.3389/fendo.2022.899731/full

Internet

https://www.frontiersin.org/articles/10.3389/fendo.2022.899731/full

Gelijkaardige items